Literature DB >> 6387916

Positron emission tomography in the study of human tumors.

R P Beaney.   

Abstract

To increase our understanding of cancer and improve cancer treatment on a rational basis we need to identify both qualitative and quantitative differences between normal and neoplastic tissue. The multimodality approach to cancer treatment includes radiotherapy, chemotherapy, hyperthermia, and immunotherapy. Most of the data on which we base our therapeutic strategies have been derived from in vitro studies or animal tumor models. More information is required on the physiology of in vivo human tumors and their response to therapy. Positron emission tomography allows the regional tissue concentration of a positron emitting radionuclide to be measured in absolute units. If valid tracer models can be formulated that accurately describe the fate of an administered "biological" tracer then the physiological process under investigation can be measured quantitatively. The sequential inhalation of C15O2, 15O2, and 11CO allows regional tissue blood flow, oxygen utilization and blood volume to be measured in absolute units. Tissue perfusion, a measure of nutrient (eg, oxygen) supply, drug delivery, or a means of heat dissipation, is of immense importance to oncologists. The oxygen-15 technique has been used not only to study regional blood flow and oxygen utilization in both tumor and normal tissue but also their response to therapeutic intervention. In those studies were tracer models are thought to be less than complete (eg, due to insufficient biological data) then only a semiquantitative or qualitative assessment of the pathophysiological state may be possible. In this respect, tumor function has been characterized by the rate of uptake of 18F-2-deoxyglucose. This technique has provided a means of tumor grading and differentiating between radiation-induced tissue necrosis and tumor recurrence. Metabolic imaging with labeled amino acids appears particularly useful in the delineation of tumor extent. Blood brain barrier integrity and the pharmacokinetics of cytotoxic drugs have also been studied quantitatively. In the future, receptor studies are likely to play an increasing role. In this review dealing with the positron emission tomography oncologic work to date, emphasis has been placed on the physiological information obtainable and how it may further our understanding of cancer and its treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6387916     DOI: 10.1016/s0001-2998(84)80006-9

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  16 in total

1.  Cancer treatment monitoring with fluorine-18 2-fluoro-2-deoxy-D-glucose and positron emission tomography: frustration or future.

Authors:  H Minn; R Paul
Journal:  Eur J Nucl Med       Date:  1992

Review 2.  Functional imaging of the brain using single photon emission computerized tomography (SPECT).

Authors:  A E Todd-Pokropek
Journal:  Brain Topogr       Date:  1992       Impact factor: 3.020

Review 3.  Blood flow and metabolic microenvironment of brain tumors.

Authors:  P Vaupel
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Recurrent malignant glioma: detection with 131I labeled monoclonal antibody G-22, positron emission tomography and magnetic resonance imaging.

Authors:  M Oshima; J Yoshida; T Wakabayashi; K Ito; M Tadokoro; T Kato; S Sakuma
Journal:  Ann Nucl Med       Date:  1993-05       Impact factor: 2.668

5.  Preparation and in vivo study of 124I-labelled monoclonal antibody H17E2 in a human tumour xenograft model. A prelude to positron emission tomography (PET).

Authors:  D E Snook; G Rowlinson-Busza; H L Sharma; A A Epenetos
Journal:  Br J Cancer Suppl       Date:  1990-07

Review 6.  Brain tumors.

Authors:  K L Black; J C Mazziotta; D P Becker
Journal:  West J Med       Date:  1991-02

Review 7.  PET in clinical oncology.

Authors:  R A Hawkins; M E Phelps
Journal:  Cancer Metastasis Rev       Date:  1988-06       Impact factor: 9.264

8.  Positron emission tomographic evaluation of radiochemotherapeutic effect on regional cerebral hemocirculation and metabolism in patients with gliomas.

Authors:  K Mineura; T Yasuda; M Kowada; T Ogawa; F Shishido; K Uemura
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

9.  Early and late stage positron emission tomography (PET) studies on the haemocirculation and metabolism of seemingly normal brain tissue in patients with gliomas following radiochemotherapy.

Authors:  K Mineura; Y Suda; T Yasuda; M Kowada; T Ogawa; F Shishido; K Uemura
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

10.  Carbon-11 labelled tyrosine to study tumor metabolism by positron emission tomography (PET).

Authors:  J M Bolster; W Vaalburg; A M Paans; T H van Dijk; P H Elsinga; J B Zijlstra; D A Piers; N H Mulder; M G Woldring; H Wynberg
Journal:  Eur J Nucl Med       Date:  1986
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.